Designing non-clinical safety evaluation programmes: The view of the toxicologist
1. Biotechnologically-derived pharmaceuticals possess unique and often species-specific biological characteristics. Their preclinical safety evaluation therefore presents unusual challenges that often preclude strict adherence to regulatory guidelines established for small-molecular-weight compounds.
KeywordsToxicity Study Safety Evaluation Reproductive Toxicity Safety Pharmacology Preclinical Safety
Unable to display preview. Download preview PDF.
- Cowgill LD (1992). Pathophysiology and management of anemia in chronic progressive renal failure. Seminars in Veterinary and Medical Surgery (Small Animal), 7(3): 175–182.Google Scholar